Physician profile
Joshua E Weitz
NPI 1790947190
$565.09
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $81.45 · 2021: $14.40 · 2023: $76.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $111.36 | 2019-2020 | |
| Allergan, INC. | $105.91 | 2019-2021 | |
| Galderma Laboratories, L.P. | $56.76 | 2020-2023 | |
| Pfizer INC. | $53.02 | 2019 | |
| Sun Pharmaceutical Industries INC. | $44.50 | 2019 | |
| Abbvie INC. | $40.36 | 2023 | |
| Novartis Pharmaceuticals Corporation | $28.39 | 2019 | |
| Amgen INC. | $21.48 | 2019 | |
| Dusa Pharmaceuticals, INC. | $19.28 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.78 | 2019 | |
| Ucb, INC. | $18.33 | 2020 | |
| Almirall LLC | $16.99 | 2019 | |
| Sandoz INC. | $15.01 | 2019 | |
| Celgene Corporation | $14.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Weitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.